Excellent article on RNAi, the use of this gene therapy via a number of companies for treatment of macular degeneration and other diseases, listing a number of GENR’s competitors, published tonight in the New York Times online:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.